Evidence-based treatment guidelines have been unable to provide evidence-based guidance on the effects of acupuncture for irritable bowel syndrome (IBS) because the only previous systematic review included only small, heterogeneous, and methodologically unsound trials. We conducted a new systematic review and meta-analysis of randomized controlled trials (RCTs) to estimate the effects of acupuncture for treating IBS. SUPPLEMENTARY MATERIAL is linked to the online version of the paper at
INTRODUCTION
Irritable bowel syndrome (IBS) is a chronic, relapsing gastrointestinal condition characterized by altered bowel habits and abdominal pain and discomfort ( 1 ) . A systematic review ( 2 ) has estimated that 10 -15 % of adults in North America have IBS, as diagnosed by either the Rome ( 3 ) or Manning ( 4 ) objective diagnostic criteria. IBS is associated with signifi cant reductions in both health-related quality of life ( 5 ) and work productivity ( 1, 6 ) and increased consumption of medical resources. Indeed, people with IBS consume over 50 % more health-care resources than age-matched controls without IBS ( 7, 8 ) . Th e combined direct and indirect costs associated with IBS patients in the United States in 2004 were estimated at over $ 1 billion ( 9 ) .
Effective treatments for IBS are needed to relieve symptoms, improve quality of life, and to reduce health-care utilization. In 2009, the American College of Gastroenterology Task Force conducted a series of systematic reviews to evaluate the efficacy of both pharmacological and nonpharmacological therapies for treating IBS ( 1 ) . In terms of pharmacological treatments, the Task Force found " poor quality of evidence " for certain antispasmodics and " moderate quality of evidence " for tricyclic antidepressants, selective serotonin reuptake inhibitors, nonabsorbable antibiotics (for diarrhea-predominant IBS), and C-2 chloride channel activators (for constipation-predominant IBS). The Task Force found " good quality of evidence " for 5HT 3 antagonists and 5HT 4 agonists, but noted that these agents carry a possible risk of ischemic colitis and cardiovascular events, respectively, which may limit their utility. A subsequent systematic review showed that the benefits of these 5HT 3 antagonists and 5HT 4 agonists relative to placebo are " modest " ( 10 ) . In terms of nonpharmacological therapies, the Task Force found " poor quality of evidence " for psyllium fiber and peppermint oil. The Task Force also noted that preliminary evidence suggested that some probiotics may be effective in reducing IBS symptoms ( 1 ) . A subsequent systematic review ( 11 ) concluded that the specific probiotic Bifidobacterium infantis 35624 has shown repeated efficacy in well-designed randomized controlled trials (RCTs), and can be considered an effective treatment for IBS.
Th e Task Force was unable to make any recommendations either for or against acupuncture for treating IBS because the only available systematic review available at the time was a 2006 Cochrane review, recently updated ( 12 ) , which was inconclusive in 2006 because it included only small, heterogeneous, and methodologically unsound trials. Given the safety of acupuncture ( 13 -15 ) and the limited availability of other safe and eff ective treatments for IBS, the question of whether acupuncture is eff ective for treating IBS is highly relevant. Recently, several RCTs have been published that provide greater evidence to estimate the eff ects of acupuncture for treating IBS. We have therefore updated our previous Cochrane systematic review and meta-analysis of acupuncture for IBS to assess whether the pooled eff ects of currently available trials show any benefi t of acupuncture in improving symptoms or health-related quality of life in patients with IBS. Th is manuscript is based on the updated Cochrane review ( 12 ) .
METHODS

Search strategy
We searched MEDLINE, the Cochrane Central Register of Controlled Trials (CENTRAL), EMBASE, the Cumulative Index to Nursing and Allied Health, and the Chinese databases Sino-Med (previously called the Chinese Biomedical Database), CNKI, and VIP (through November 2011). We considered all RCTs included in, or ongoing, at the time of the 2006 version of our Cochrane review ( 12 ) . To further avoid the risk of missing eligible trials ( 16 ) , we also scanned bibliographies of included articles and systematic reviews for further references.
Study selection
We included RCTs, published in any language, as either full articles or abstracts. Because recent research indicates that a large proportion of Chinese-language RCT reports are of studies that are not truly randomized ( 17 ) , an author interviewed the investigators of Chinese-language RCTs by telephone to determine whether they had used randomization. Th e interviews were conducted using questions adapted from the survey developed by Wu et al. ( 17 ) to verify the authenticity of " claimed " randomized trials. Th e same questions were asked of authors of English-language RCTs that did not include details about randomization methods in their published reports. Trials that were found to assign patients by alternation, rotation, or hospital record number were automatically excluded. Trials that used a random method of assignment, but with fl aws or suspected fl aws in the random assignment process, were included, but with their limitations described.
We included trials evaluating Traditional Chinese Medicine (TCM) acupuncture for the treatment of adults diagnosed with IBS. TCM acupuncture involves inserting needles into traditional meridian points, usually with the intention of infl uencing energy fl ow in the meridian. Needles may also be inserted at additional tender points and electrical stimulation of the needles may be used. As TCM acupuncture is oft en accompanied by moxibustion, we included trials using moxibustion as a co-intervention with acupuncture. We excluded trials of dry needling / trigger point therapy, a therapy that is based on principles of Western anatomy and physiology and rejects TCM concepts of energy and meridians. We also excluded RCTs of laser acupuncture, noninvasive electrostimulation (i.e., using electrodes on the skin rather than needles to stimulate acupuncture points ( 18 )), and acupressure to restrict our focus to the eff ects of traditional needle acupuncture. Finally, we excluded trials of micropuncture, a nontraditional acupuncture practice that is based on the principle that the ear (or nose, eye, etc.) is a microsystem of the entire body, and in which needles are only inserted on that microsystem.
We included trials comparing acupuncture with sham (placebo) acupuncture, other active non-TCM treatments, and no (specifi c) treatment, or evaluated acupuncture as an adjuvant to another treatment. We excluded RCTs in which one form of acupuncture was compared with another form of acupuncture or a diff erent type of TCM (e.g., Chinese herbal medicine). Adjunctive treatments, either Western or TCM, were allowed as long as they had been given to both the acupuncture and control groups. Our
All study characteristics and outcome data were independently extracted by two authors, and disagreements were resolved by discussion. When reported data were incomplete or ambiguous, we requested additional information or clarifi cation from the corresponding authors.
Assessment of acupuncture adequacy
Two acupuncturists (L.L. and X.S.) who have a combined acupuncture clinical experience of nearly 50 years in treating IBS, and who have previously worked on RCTs of acupuncture, assessed the adequacy of the acupuncture administered in the trials. Six aspects of the acupuncture intervention were assessed for adequacy: choice of acupuncture points, total number of sessions, treatment duration, treatment frequency, needling technique, and acupuncturist ' s experience ( 25 -27 ) . Th e likelihood of the sham intervention to have physiological activity was also assessed, using an open-ended question. Th e acupuncturist assessors were provided with only the part of the publications that described the acupuncture and sham procedures, so that their assessments could not be infl uenced by the results of the trials. To test the success of blinding the assessors to the study publication and results, we asked the assessors to guess the identity of each study being assessed. Th e acupuncturists assessed adequacy independently and achieved consensus by discussion.
Study risk of bias
For each included study, we assessed the risk of bias using the Cochrane Collaboration ' s risk of bias tool ( 28 ) , which comprises six domains that may increase the risk of over-or underestimating an intervention eff ect. We also evaluated two other risks of bias-related factors: baseline comparability and use of an ITT analysis.
In judging adequacy of blinding, which is one of the Cochrane risk of bias domains, we assigned sham-controlled trials a judgment of " Unclear " unless we felt certain that the sham control was suffi ciently credible in fully blinding participants to the treatment being evaluated ( 26, 27 ) . We considered sham-controlled trials to have a low risk of bias for blinding if the trial either (i) evaluated the credibility of the sham and found the sham to be indistinguishable from true acupuncture or (ii) used a penetrating needle or a previously validated sham needle (i.e., Streitberger needle ( 29 )).
Two review authors independently judged whether each risk of bias criterion was adequately met. Any disagreement was resolved by discussion.
Data synthesis and statistical analysis
We only pooled data from trials that used similar control interventions (sham acupuncture, no treatment, or another active treatment), outcome measures (overall IBS symptom severity, IBSrelated quality of life), and timing of outcome assessment (short term and long term). For pooled data, summary test statistics were calculated using the RevMan soft ware, version 5.1 ( 30 ) random eff ects model to account for expected heterogeneity. We evaluated heterogeneity using the I 2 statistic ( 31 ), which indicates the proportion of variability across trials not explained by chance alone ( 32 ) . primary outcomes were overall IBS symptom severity and IBS health-related quality of life. Studies that did not report at least one of these outcomes were excluded.
All records identifi ed by searching were independently screened by at least one reviewer. Th e full text of potentially relevant reports was obtained and independently reviewed by two authors for eligibility. Disagreements between reviewers were resolved by discussion.
Outcome measures and data extraction
Two recent evaluations of symptom and quality-of-life measures in IBS concluded that the IBS Adequate Relief question (IBS-AR) ( 19 ) and the IBS Symptom Severity Scale (IBS-SSS) ( 20 ) possessed responsiveness, face, and construct validity, and were two of the most appropriate IBS symptom outcome measures, whereas the IBS Quality-of-Life measure (IBS-QoL) ( 21 ) was the most extensively validated quality-of life-scale ( 22, 23 ) . For overall symptom severity, we therefore gave preference to the IBS-AR for dichotomous outcomes and to the IBS-SSS for continuous outcomes, whereas for quality-of-life outcomes we gave preference to the IBS-QoL. In cases where dichotomous outcomes such as improvement in IBS symptoms were presented in the form of multiple strata, such that we had the option of choosing cut points for the dichotomous outcome, we followed the model of Ford et al. ( 10, 24 ) and created a dichotomous measure in which all positive outcomes were combined into a single positive category (i.e., improvement) and the remaining strata constituted the negative category (i.e., no improvement). When investigators selected a cut point on a continuous scale to dichotomize between improvement and no improvement, we used the same cut point to defi ne the dichotomous outcome ( 10 ) .
We extracted outcome data for both short-and long-term follow-up points. Short-term follow-up was defi ned as 3 months aft er randomization, and long-term follow-up was defi ned as closest to 6 months but >3 months aft er randomization. When we observed multiple short-term follow-up points, we chose to extract the data closest to 8 weeks aft er randomization, which coincided with end of treatment. In cases where participants were lost to follow-up, and the RCT investigators conducted intention-to-treat (ITT) analyses using imputed values for the participants ' missing data, we used these ITT results for our meta-analyses in preference to the available case analyses, if the ITT method for imputing data was described and if it was an appropriate method that would not bias the eff ect size calculation. If the method that the RCT investigators used for imputing missing data in their ITT analysis was not clearly described or not appropriate, we used the available case data instead (if available) for the primary analysis and the ITT data for a sensitivity analysis. If either only the ITT data or only the available case data were reported, then those available data were used. (We did not impute missing data ourselves for the meta-analyses). Th e potential impact of missing data (including missing data that were imputed using a method that was not clearly described) were considered in interpreting the results of the review, taking into account the degree of missing trial data across the treatment arms and the size of the eff ect estimate of the individual trial and the pooled eff ect estimate. For the acupuncture vs. sham comparison, data for the symptom severity outcome were presented in some studies as dichotomous data (e.g., adequate symptom relief) and in other studies as continuous data (e.g., symptom severity as measured by the IBS-SSS). We re-expressed odds ratios as standardized mean diff erences (SMDs), thereby allowing dichotomous and continuous data to be pooled together for this comparison / outcome ( 32 ), using the generic inverse variance method in RevMan. For the acupuncture vs. sham comparison, all 3 studies that included the qualityof-life outcome reported continuous data (and 2 out of 3 did not also report dichotomous data), and hence we pooled these studies using the SMD. For all other comparisons / outcomes, all studies reported dichotomous outcome data (and some did not also report continuous data), and hence we pooled these studies as relative risks (RRs). For the Cochrane version of this review, all continuous and dichotomous data reported for all studies are presented in forest plots. Th ere were no important diff erences between continuous and dichotomous results for any comparison / outcome.
RESULTS
Results of the search
Our searches identifi ed 1,421 citations of which 71 references, corresponding to 65 individual studies, were evaluated in full. Of these 65 studies, 48 were excluded, leaving 17 eligible RCTs ( 33 -49 ) , including a total of 1,806 patients (see Supplementary  Figure S1 online ). Th ree of the studies included in our 2006 Cochrane review ( 50 -52 ) were excluded from this update because either an adequate randomization process was not used ( 50, 51 ) or the procedure could not be recalled by the author ( 52 ) . Table 1 includes a description of trial characteristics and acupuncture and control interventions. Th e Cochrane version of this review ( 12 ) includes an additional fi gure for the fl ow of studies through the selection process, as well as the following additional tables: summary of fi ndings table; list of studies that we excluded as well as the reasons for exclusion; full details of the characteristics of the included trials; full details of the risk of bias assessments for each trial; and assessments of adequacy of acupuncture and sham protocols.
Acupuncture adequacy
All trials included in this review were judged adequate on " Choice of acupoints, " except for the Lowe trial ( 42 ), which did not report the acupoints. Th e acupuncture frequency was judged adequate in all trials except for the Forbes and Reynolds trials ( 37, 43 ) . Th e acupuncture adequacy assessors were successfully blinded to the study publications and were unable to guess the identity or results of any of the studies they assessed.
Risk of bias in included studies
All sham-controlled trials reported adequate methods for sequence generation and allocation concealment. In four out of fi ve shamcontrolled trials ( 34, 37, 38, 44 ) (i.e., all except for the Lowe trial ( 42 )), we judged that the shams were likely to be indistinguishable from true acupuncture and that incomplete outcome data were adequately addressed. Th e Lowe trial was reported only as an abstract, and the completeness of outcome data ascertainment could not be assessed. In one sham-controlled trial ( 37 ) that had a moderate total number of withdrawals (i.e., 8 / 59), the dropouts were approximately evenly distributed across treatment groups, the withdrawals were unlikely to be related to knowledge of treatment assignment or eff ects of the treatment, and the degree of missing data would be unlikely to aff ect the estimate of the treatment eff ect in this individual trial or in the meta-analytic estimates.
In the trials comparing acupuncture with another active treatment ( 33, 35, 40, 41, 45, 46, 48, 49 ) , no (specifi c) treatment ( 38, 43 ) , or evaluating acupuncture as an adjuvant to another treatment received by all trial participants ( 36,39 -41,47 ) , blinding of participants was not possible, and this likely represents the major risk of bias in these trials. In these comparative eff ectiveness trials, there were also risks of bias associated with the randomization procedure and the follow-up of patients (see risk of bias; Table 2 ) .
Acupuncture vs. sham acupuncture
Five trials ( 34, 37, 38, 42, 44 ) 
Acupuncture vs. other active treatments
Th e fi ve trials ( 35, 45, 46, 48, 49 ) that compared acupuncture vs. pharmacological therapies for IBS found that participants receiving acupuncture reported a greater improvement than participants receiving pharmacological therapies (see Figure 2 ).
Participants receiving acupuncture were not more likely to have responded to treatment than those treated with psychotherapy ( 40 ) or those treated with bifi dobacterium ( 33, 41 ) .
Acupuncture as an adjuvant to other active treatments
Five trials ( 36,39 -41,47 ) compared the combination of adjuvant acupuncture plus another IBS treatment received by all trial participants with the other IBS treatment alone. Pooled results showed that participants receiving adjuvant acupuncture were more likely to have reported improvement than those treated with another Chinese medicine treatment alone (although there was substantial heterogeneity of results and high risks of bias in these trials) ( 36, 39, 41, 47 ) , or those treated with psychotherapy alone ( 40 ) .
Acupuncture vs. no specifi c treatment
Two trials ( 38, 43 ) compared the eff ects of acupuncture with no specifi c treatment. In both trials, all participants were allowed to continue receiving standard medical care for IBS, including prescribed medications, but control group participants were not assigned to any additional IBS treatment. Both of these trials showed a statistically signifi cant benefi t of acupuncture for improving IBS symptom severity, although there was substantial heterogeneity of results between the two trials ( I 2 = 57 % ).
Subgroup and sensitivity analyses
For the sham-controlled trials, subgroup analyses on the risk of bias or treatment adequacy-related variables would be uninformative because all sham-controlled trials had similar results, and no combination of these trials resulted in a pooled statistically signifi cant benefi t for either the symptom severity or quality-of-life outcome. For trials comparing acupuncture vs. pharmacological therapies, restriction to the four trials that compared acupuncture vs. evidence-based ( 53 ) antispasmodic pharmacological therapies ( 35, 45, 46, 49 ) had similar results (RR 1.21, 95 % CI: 1.07 to 1.37, 249 participants, I 2 = 0). For the other comparisons, there were too few trials to attempt subgroup analyses ( 32 ) .
For the Forbes et al. ( 37 ) , trial which reported both ITT and available case data for the symptom severity outcome, a sensitivity analysis using ITT values instead of the available case values did not result in important diff erences in the SMDs for this trial.
Safety of acupuncture
A total of nine trials included descriptions of adverse events associated with acupuncture ( 33,34,36 -38,41,43,45,46 ) . For eight of these nine trials ( 33,34,36 -38,41,43,46 ) , no serious adverse events were reported, whereas the Shi et al. ( 45 ) trial reported that one participant in the electroacupuncture group withdrew because of syncope. The time point listed is the number of weeks after randomization. c For these two trials, the author did not record or recall the numbers randomized, or the numbers of dropouts, and the numbers analyzed are reported here. For all 11 trials conducted in China, a symptom scale was used to assess the severity of the patients ' overall IBS-related symptoms (e.g., abdominal pain, defecation diffi culties, diarrhea) both at baseline and after treatment. For eight of these trials (33,35,36,41,45 -47,49) , a percentage improvement from baseline scores was then calculated (i.e., (baseline symptom score -symptom score after treatment) / baseline symptom score), and this percentage change from baseline was then grouped into two (45), three (33, 49) , or four ( 35, 36, 41, 46, 47 ) categories, which were then converted into two categories for the meta-analysis, as described in the Methods section. For the other three trials (39, 40, 48) , it was not clear how the symptom scale scores were converted into the categorical data. For these 11 trials, the criteria for improvement are listed as " Categorical " in this table. e A dash ( -) indicates that the outcome was not measured. In this trial, patients were randomized to fi ve arms. The fi rst arm was a waitlist control. Participants in the remaining four arms were randomized to sham or true acupuncture, with or without an augmented practitioner -patient interaction. There was no main effect of practitioner -patient interaction; therefore, we combined the two acupuncture groups (augmented and limited encounter) and the two sham acupuncture groups (augmented and limited encounter) in order to compare the effects of acupuncture and sham acupuncture. 
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Acupuncture for IBS Systematic Review the same time, fi ve Chinese-language comparative eff ectiveness trials found that patients receiving acupuncture reported greater improvements in IBS symptoms compared with patients receiving pharmacological therapies for IBS.
How should physicians, researchers, and policymakers interpret these seemingly contradictory trial fi ndings, i.e., that acupuncture had no greater eff ects than a sham/placebo, but acupuncture did show greater eff ects compared with 2 pharmacological treatments that have both previously been shown to be superior to a placebo ( 53 )? First, both the comparative eff ectiveness trials and
DISCUSSION
Summary of main results
Five sham-controlled RCTs have tested the eff ects of acupuncture for IBS, and four of these trials used adequate randomization, blinding, and had few withdrawals / dropouts. None of these sham-controlled RCTs individually found a statistically signifi cant benefi t of acupuncture relative to sham acupuncture on the outcomes of symptom severity or quality of life. Similarly, pooling the data from these sham-controlled trials did not result in statistically signifi cant benefi ts of acupuncture on either outcome. At Additional data obtained from RCT authors are enclosed in brackets to allow such data to be differentiated from the data included only in the publications. b For the baseline comparability criterion to score " Yes, " a comparison of the symptom scores between the treatment and control group(s) at baseline needed to be reported. c For the intention-to-treat (ITT) criterion to score " Yes, " an ITT analysis needed to be reported. d In these trials, the authors did not report the numbers of dropouts in their publication, and did not have records of the numbers of dropouts to provide during the telephone interviews. e For the sham control, penetrating needles were superfi cially inserted at nonpoints that were 2-3 cm away from the true points, and placebo moxibustion was performed above the same sham points without generating a heat sensation. f The authors of these trials confi rmed in telephone interviews that a few patients were nonrandomly assigned to achieve identical-sized treatment groups. g For this trial, the authors endeavored to maintain equal group sizes by eliminating participants who withdrew during the trial and replacing them with new patients, and the number of such replacements was not recorded by the author. h For the sham control, acupuncture needles were inserted at areas on the body that do not correspond to acupuncture points and are deemed to have no therapeutic value. The points and needling technique were varied somewhat each week, as was also done in the true acupuncture group, who received individualized point selection.
i For the sham control in these trials, the Streitberger placebo needle was used, which has been previously validated as a suffi ciently credible sham ( 29 ) . The Streitberger needles were placed close to the genuine acupuncture points in both trials. In both trials, the participants were acupuncture na ï ve. j This criterion was scored as " Unclear " because the authors of these three trials were unable to explain how equal sample sizes were achieved. k For this trial, the authors reported no dropouts, which would be unusual in a 4-week trial of 300 participants. The sham control used in this trial was judged to have been potentially detectable as a fake treatment by the trial participants. The sham procedure involved tapping a blunt needle on the skin and then taping the needle in place. Although this procedure was described as " validated, " we are unaware of a validation study for this procedure. Also, in the trial report there was no description of whether or not the patients were required to have never previously used acupuncture, and there were no reported tests for checking the success of the blinding.
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the sham-controlled trials have important limitations that complicate their interpretations. Namely, an important limitation of the trials comparing acupuncture versus pharmacological therapy is that the patients in these trials are not " blinded " to whether they received acupuncture or drugs, and expectation eff ects (i.e., defi ned as " the impact of expectations on subjective outcomes " ( 54 )), may diff er between acupuncture and drugs ( 27, 55, 56 ) . Th at is, if patients randomized to acupuncture expect greater improvements than patients random ized to drugs, the greater expectations of benefi ts from acupuncture may contribute to a larger placebo eff ect (i.e., a larger improvement in symptoms due to an inert treatment, or an inert component of a treatment) in the acupuncture group than in the drug group. Because of the possibility of diff erential expectations of a benefi t from acupuncture vs. drugs in these trials ( 27, 55, 57 ) , it cannot be determined whether any of the reported benefi ts of acupuncture are due to a larger biological eff ect of acupuncture needling relative to drugs, or rather due entirely to the impact of the trial participants ' greater expectations of a benefi t of acupuncture, on the subjective outcomes that they reported.
A limitation of the sham-controlled trial design is that the high placebo eff ects of sham acupuncture may preclude the detection of any small, true biological benefi ts of true acupuncture relative to a credible sham acupuncture control, when subjective patient self reports are the outcome measures used. Two " methodological " trials have evaluated the placebo eff ects of sham acupuncture on both subjective and objective outcome measures ( 56, 58 ) . One such methodological trial ( 56 ) designed to compare placebo eff ects of placebo pills and sham acupuncture found that, relative to placebo pills, sham acupuncture was more credible as an authentic treatment and resulted in higher subjective patient self reports of improvement. Th is trial also found that the placebo eff ect was confi ned to self-reported, subjective outcomes (e.g., pain) and that there was no placebo eff ect (i.e., no improvement from baseline) for either the placebo acupuncture or placebo pill on the objective outcome that they measured (i.e., grip strength). Another recent methodological trial ( 58 ) compared albuterol (i.e., a proven asthma drug) vs. sham acupuncture for asthma patients, and found that although only albuterol had a biological eff ect on the objective outcome of airway fl ow, both the sham acupuncture and albuterol groups had dramatic and comparable improvements from baseline on the subjective outcome of patient self-reports of improvement, such that albuterol showed no benefi t relative to the sham acupuncture on self-reported improvement.
Th ese methodological trials suggest that relying exclusively on subjective patient reports, such as those used as outcomes in IBS trials, may result in a failure to detect small biological eff ects of an active treatment (i.e., true acupuncture) relative to a highly credible, but physiologically inert, sham acupuncture control. Th us, although the high placebo eff ects among IBS patients ( 59 ) make it diffi cult to show that any pharmacological treatment is superior to an inert placebo pill, demonstrating such an eff ect may be even more diffi cult when the placebo control is sham acupuncture.
Overall completeness and applicability of evidence
How externally valid are the results of this review? Namely, do the types of interventions investigated in these studies represent current best practice of acupuncture for IBS? Assessing adequacy 
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formulating conclusions about the effi cacy of a drug based on an inadequate dose " ( 60 ) . For the sham-controlled trials, it might be argued that a possible reason for the lack of benefi t might be of the acupuncture treatment procedure is important because, for instance, basing conclusions about acupuncture effi cacy on a suboptimal procedure is " analogous to a pharmaceutical trial explained by the fact that there was an inadequate number of treatment sessions, an insuffi cient duration of treatment, or an inadequate treatment frequency. However, all sham-controlled trials were judged by our acupuncture adequacy assessors to have used an adequate number of treatment sessions and a suffi cient duration of treatment. Only the Forbes sham-controlled trial ( 37 ) was judged to use an inadequate treatment frequency because this trial involved only one acupuncture session per week (for 13 weeks), which although judged inadequate, probably still well refl ects clinical practice in the West. Th e other sham-controlled trials all used two sessions per week, which was judged by the acupuncture adequacy assessors as an adequate treatment frequency, and hence it seems unlikely that an inadequate frequency of treatment explains the lack of benefi t. Although the acupuncture assessors judged the treatment frequency of the sham-controlled trials to be largely adequate, the Chinese-language comparative eff ectiveness trials used a much greater treatment frequency, with daily acupuncture treatments used in 9 out of 11 of these comparative eff ectiveness trials, and all 5 of these trials that compared acupuncture vs. drugs. Th e higher acupuncture treatment frequency in the Chinese comparative eff ectiveness trials, relative to the sham-controlled trials, might also help explain the diff erent benefi ts of acupuncture relative to the controls in these two subsets of trials.
Quality of the evidence
Out of the fi ve sham-controlled trials in this review, four ( 34, 37, 38, 44 ) did not have limitations related to a risk of bias criterion. Only the trial by Lowe ( 42 ) used a sham intervention that might not have been suffi ciently believable as true acupuncture; however, if the sham acupuncture group participants realized they were getting a sham treatment, then this unblinding to the treatment received would likely have only resulted in an overestimate of the eff ects of true acupuncture in this trial. It might be argued that one potential methodological limitation is that two of the fi ve sham-controlled RCTs ( 34,37 ) used a sham control that involved skin-penetrating needles inserted at nonacupuncture points that the acupuncture assessors in our review judged to have potential weak physiological activity that might infl uence the outcome, and which might therefore have biased these two RCTs to the null. However, we would not expect this to explain the lack of benefi t of acupuncture relative to sham, because these two shams were judged to have potential for only weak physiological activity and also because the other three sham-controlled RCTs used shams that were judged unlikely to have physiological eff ects, and these three RCTs also found no benefi t of acupuncture relative to sham.
Th e quality of the evidence is also limited by the fact that all shamcontrolled trials except the Lembo trial ( 38 ) had small sample sizes and were each underpowered to detect a small benefi t of the acupuncture protocol evaluated. Although these trials may have been adequately powered to detect a moderate-to-large benefi t of acupuncture relative to sham, an eff ect size of this magnitude may have been unreasonable to expect, considering that even specifi c 5HT 4 agonists (i.e., tegaserod) and 5HT 3 antagonists (i.e., alosetron and cilansetron), which are the only treatments with " good quality of evidence " for treating IBS ( 1 ), have only a modest effi cacy. Although a meta-analysis of the fi ve sham-controlled trials increases the statistical power to detect an eff ect, a limitation of pooling trials with diff erent acupuncture protocols is that we cannot rule out the possibility that larger trials or meta-analyses focusing on one of these protocols might show a benefi t of treatment. In addition, although our meta-analysis point estimates suggest no eff ects, our metaanalysis CIs include the possibility that there could be small benefi ts that could be important to patients. A fi nal limitation of the sham-controlled trial evidence base related to the small sample sizes and also the heterogeneity of participants is that these trials did not restrict eligibility to specifi c subtypes of IBS patients, and the proportions of patients with diff erent IBS subtypes diff ered across trials. An individual patient data meta-analysis would be necessary to address whether acupuncture has diff erent eff ects on diff erent subtypes of IBS patients, although the relatively small numbers of patients would be unlikely to provide a confi dent answer to this question.
In the Chinese-language comparative eff ectiveness trials, in addition to the primary risk of bias associated with the absence of patient blinding, there were also risks of bias associated with the randomization procedure and the follow-up of patients. Notably, for fi ve of these trials ( 36,39 -41,48 ) , there were equal-sized treatment groups, and the trial investigators could not adequately explain during our telephone surveys how this was achieved. Th is raises the possibility that the randomization might not have been adequately generated or concealed ( 61 ) . Th e notion that randomized trials should have equal numbers in each treatment group has been shown to commonly lead clinical trial investigators to force equality by unscientifi c means ( 61 ) . Indeed, previous methodological reviews of this issue have found that over one-half of trials using simple, unrestricted randomization schemes report equal numbers in each group ( 61, 62 ) , and 88 % of reported randomized trials have been shown to exclude some randomized participants from their analysis ( 62 ) . Th e Chinese trials with high risks of bias associated with the randomization and / or the accounting of randomized patients in the outcomes assessments evaluated acupuncture as an adjuvant to either another Chinese medicine treatment or psychotherapy, or compared acupuncture vs. psychotherapy, probiotics, or a drug not indicated or commonly used for IBS (i.e., sulfasalazine ( 48 )). Th erefore, the fi ndings from these comparisons should be considered only hypothesis generating, and are not included in our overall conclusions. In contrast, there was an overall low risk of bias in the four comparative eff ectiveness trials that found acupuncture more eff ective than two antispasmodic pharmacological therapies shown to be eff ective for IBS ( 53,63 ) (i.e., pinaverium bromide ( 35, 45, 46 ) and Trimebutine maleate ( 49 )).
Authors ' conclusions
Implications for practice . People with IBS have few treatment options available. Pharmacological therapies have modest benefi ts ( 24 ) , can have high costs, and some of the newer drugs have been withdrawn from the market because of side eff ects ( 64, 65 ) . Safe, nonpharmacological therapies that may allow patients to feel more empowered and more in control of their symptoms
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Anastasi; n = 171). Th is trial compares a sham control with two diff erent acupuncture test treatment groups, one test group using a fi xed formula and the other test group using an individualized treatment approach, for patients with diarrhea-predominant IBS. If this trial shows no benefi t of acupuncture relative to the sham, then the need for additional sham-controlled trials would seem questionable. However, if this ongoing sham-controlled trial shows a benefi t, then future sham-controlled trials building upon the results of this trial (e.g., restriction to diarrhea-predominant IBS patients; using the same acupoints as used in this trial) would certainly be warranted. Such future sham-controlled trials should use nonpenetrating, but demonstrably credible, shams to control for placebo eff ects, and ideally these sham needles should be placed far away from the true acupuncture points.
Because of the diffi culties of controlling for placebo eff ects in acupuncture for IBS trials, which typically evaluate strictly subjective, patient-reported outcomes (e.g., symptom severity, quality of life), another approach forward for research is the evaluation of objective or semi-objective outcomes in IBS patients, using pragmatic and cost-eff ectiveness trials. Indeed, a recently completed trial ( n = 220; Principal Investigator: MacPherson) compared the eff ectiveness and cost eff ectiveness of acupuncture plus usual general practitioner care vs. usual general practitioner care alone on the semi-objective outcomes of medication use, health service use, and days lost from work ( 69 ) . Although this trial does not include a placebo control, because the outcome measures being assessed in this trial are semi-objective, its results will be less infl uenced by expectation eff ects ( 70 -72 ) than trials that assess only strictly subjective outcomes (i.e., patient reports of symptom improvement). Indeed, the Rome criteria for design of IBS treatment trials note that placebo eff ects " are especially a problem where end points are subjective ( 23 ) . " If this recently completed cost-eff ectiveness trial shows that acupuncture reduces health-care utilization, then whether the resulting cost savings are because of a specifi c eff ect of acupuncture needling or nonspecifi c eff ects (e.g., greater autonomy and empowerment of patients, positive patientpractitioner relationship) seem of secondary importance. However, it must be borne in mind that the patient population who elected to participate in this acupuncture trial may have stronger a priori beliefs about the benefi ts of acupuncture than does the average population of IBS patients, and therefore the nonspecifi c eff ects experienced by the patients in this unblinded trial may not be generalizable to the results that would be obtained among the average population of IBS patients. However, this trial ' s results may still be generalizable to the subset of IBS patients in general practice who would elect to receive acupuncture because such patients may also have a priori expectations for acupuncture to be beneficial. To produce results generalizable to the average population of IBS patients, investigators of future pragmatic trials might minimize the recruitment of participants with an a priori preference for acupuncture by not specifying, in the recruitment of patients, that acupuncture is one of the treatment options being investigated.
Future comparative eff ectiveness trials would also be helpful to validate and extend the preliminary evidence in this review, which suggests that acupuncture is associated with greater improvements should be evaluated for eff ectiveness. However, evaluating such complex nonpharmacological therapies for IBS (e.g., mindfulness meditation ( 66 ) and hypnotherapy ( 67 )) poses challenges, particularly with regard to selecting a placebo control or a credible alternative treatment control.
Although acupuncture can theoretically be compared with a sham acupuncture " placebo " control, a fundamental challenge has been developing a sham acupuncture control that is suffi ciently believable to patients as to be indistinguishable from true acupuncture, and yet at the same time not so similar to true acupuncture that the sham has a therapeutic eff ect of its own and is therefore not an inert placebo. Th e sham acupuncture controls used in four of the fi ve sham-controlled trials in this review appeared to be believable as authentic treatments, but two of the fi ve sham-controlled trials used sham controls that might have had weak physiological activity, and therefore these shams may not have been completely inert placebos. Although none of the sham-controlled trials showed a benefi t of acupuncture relative to sham acupuncture, it is still not clear whether these fi ndings are because acupuncture has no true biological eff ect above and beyond a placebo, or whether instead acupuncture has small biological eff ects, but the small sample sizes and heterogeneity of participants and interventions in these trials precluded detecting a statistically signifi cant pooled benefi t of acupuncture over sham, or whether any biological eff ects of true acupuncture cannot be detected because they are overridden and obscured by the large placebo eff ects of the sham control ( 56, 58 ) . Evidence from four Chinese-language comparative eff ectiveness trials ( 35, 45, 46, 49 ) showed acupuncture to be superior to the two antispasmodic drugs, both of which have consistently been shown to be eff ective in high-quality trials ( 53, 63 ) , although neither of them is approved for treatment of IBS in the United States ( 63 ) . Patient preferences and expectations may partly explain the positive fi ndings of these trials comparing acupuncture with drugs. Th at is, if the trial participants have pretreatment preferences for acupuncture over drugs, these preferences may have infl uenced the participants ' later assessments of their subjective states, as reported on the patient-reported outcome measures used ( 27, 55, 57, 68 ) .
In addition to effi cacy, safety and costs are other considerations. Safety is best determined with large prospective surveys of practitioners, and three such surveys ( 13 -15 ) show that serious adverse events aft er acupuncture are rare. Th ere was one adverse event associated with acupuncture in the nine trials that reported this outcome ( 33,34,36 -38,41,43,45,46 ) , although relatively small sample sizes limit the usefulness of these safety data. Finally, patients would also need to consider costs because acupuncture treatment oft en needs to be paid for out of pocket, at least in part.
Implications for research . Considering that our meta-analysis found no diff erences between acupuncture and sham, and also considering that there are limited resources available to conduct trials of acupuncture, a nonproprietary therapy, additional shamcontrolled trials of acupuncture among IBS patients should not be a high priority in acupuncture research, at least until the large, ongoing sham-controlled trial, which is expected to complete data collection in March 2013, is published (Principal Investigator: in subjective patient self-assessments than pharmacological therapies. As previously mentioned, a limitation of the acupuncture vs. pharmacological therapy trials in this review is that they did not use a design that controlled for the eff ects of patients ' expectations for improvement, patient preferences, and nonspecifi c therapeutic factors. Indeed, in the Chinese trials included in this review, the patients may well have had pretreatment preferences for acupuncture, considering that these trials were conducted at hospitals of traditional Chinese medicine. Because acupuncture may elicit a greater expectation eff ect than pharmacological therapies or other active treatments ( 27, 55, 56 ) , particularly among participants who have a preference for acupuncture, investigators conducting future trials that compare acupuncture with other active therapies should consider asking participants about their preferences and expectations (before and aft er the intervention), and studying the potential eff ects of pretreatment preferences on study outcomes. Such trials should also include a credibility questionnaire to establish that the treatments being compared are perceived by the patients as equally credible treatments for IBS symptoms ( 66 ) . Future comparative eff ectiveness trials in the West should also consider using a daily frequency of acupuncture, as was used in the Chinese trials in this review. However, even with additional well-designed trials, the truth about the eff ects of acupuncture for IBS will likely always be diffi cult to assess because the complexities and potential biases inherent to both the comparative eff ectiveness and sham acupuncture control designs makes it difficult to evaluate the subjective, patient-reported outcomes typically used in IBS trials.
